Key Points
A case-study approach is used to show that screening approved, and frequently off-patent, drugs efficiently yields candidate medications suitable for clinical trials.
The first two cases highlight cell-based screens that identified medications potentially useful for amyotrophic lateral sclerosis and progressive multifocal leukoencephalopathy, and clinical trials are being planned to test both types of medications.
Screening off-patent and off-market medications also led to the discovery of the molecular target responsible for the serious side-effects of the 'Fen/Phen' appetite suppressant combination and to a rational approach to anorectic drug discovery and development.
Using a similar approach, candidate medications have also been identified for multiple myeloma (fluphenazine), Alzheimer's disease (non-steroidal anti-inflammatory drugs and glitazones) and various psychiatric disorders
Screening all clinically approved medications against both the 'druggable genome' and an array of cell-based readouts is predicted to yield a large number of new therapeutics.
Abstract
With the annotation of the human genome approaching completion, public-sector researchers — spurred in part by various National Institutes of Health Roadmap Initiatives — have become increasingly engaged in drug discovery and development efforts. Although large and diverse chemical libraries of 'drug-like' compounds can be readily screened to yield chemically novel scaffolds, transforming these 'chemical probes' into drugs is a daunting endeavour. A more efficient approach involves screening libraries of approved and off-patent medications; both phenotypic- and molecular target-based screening of 'old drugs' can readily yield compounds that could be immediately used in clinical trials. Using case studies, we describe how this approach has rapidly identified candidate medications suitable for clinical trials in disorders such as progressive multifocal leukoencephalopathy and amyotrophic lateral sclerosis. This approach has also led to the discovery of the molecular targets responsible for serious drug side effects, thereby allowing efficient 'counter-screening' to avoid these side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931–945 (2004).
Zerhouni, E. Medicine. The NIH Roadmap. Science 302, 63–72 (2003).
Austin, C. P., Brady, L. S., Insel, T. R. & Collins, F. S. NIH Molecular Libraries Initiative. Science 306, 1138–1139 (2004).
Duyk, G. Attrition and translation. Science 302, 603–605 (2003).
Couzin, J. Molecular medicine. NIH dives into drug discovery. Science 302, 218–221 (2003).
Strausberg, R. L. & Schreiber, S. L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294–295 (2003).
Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360–364 (2004).
Haggarty, S. J., Clemons, P. A. & Schreiber, S. L. Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J. Am. Chem. Soc. 125, 10543–10545 (2003).
Armbruster, B. N. & Roth, B. L. Mining the receptorome. J. Biol. Chem. 280, 5129–5132 (2005).
Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353–359 (2004).
Coito, C., Diamond, D. L., Neddermann, P., Korth, M. J. & Katze, M. G. High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J. Virol. 78, 3502–3513 (2004).
Johnson, S. A. & Hunter, T. Kinomics: methods for deciphering the kinome. Nature Methods 2, 17–25 (2005). In references 11 and 12 the approach for screening the 'kinome' is validated.
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).
Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nature Rev. Drug Discov. 3, 673–683 (2004).
Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nature Rev. Drug Discov. 4, 71–78 (2005).
Pharmaceutical Researcher Manufacturers of America. Pharmaceutical Industry Profile 2005 [online], <http://www.phrma.org/publications/publications/17.03.2005.1142.cfm> (2005).
McCaig, L. F., Besser, R. E. & Hughes, J. M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerging Infect. Dis. 9, 432–437 (2003).
Rothstein, J. D. et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73–77 (2005). A pivotal paper in which cleverly designed phenotypic screens are used to identify a promising treatment strategy for a serious disease involving drugs already approved for human use.
Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675–686 (1996).
Maragakis, N. J., Dykes-Hoberg, M. & Rothstein, J. D. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol. 55, 469–477 (2004).
Beghi, E., Bendotti, C. & Mennini, T. Merits of a new drug trial for ALS? Science 308, 632–633; author reply 632–633 (2005).
Couratier, P., Vallat, J. M., Merle, L., Preux, P. M. & Hugon, J. Report of six sporadic cases of ALS patients receiving ceftriaxone. Therapie 49, 146 (1994).
Carelli, V., Liguori, R., Cordivari, C., Bianchedi, G. & Montagna, P. Ceftriaxone is ineffective in ALS. Ital. J. Neurol. Sci. 15, 66 (1994).
Koralnik, I. J. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17, 365–370 (2004).
Schreiner, B., Kieseier, B. C., Hartung, H. P., Hohlfeld, R. & Wiendl, H. Blocking adhesion molecules with natalizumab in multiple sclerosis. Nervenarzt 76, 999–1005 (2005).
Imperato, A. K., Bingham, C. O. & Abramson, S. B. Overview of benefit/risk of biological agents. Clin. Exp. Rheumatol. 22, S108–S114 (2004).
Elphick, G. F. et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306, 1380–1383 (2004). In this paper, the authors use a combination of phenotypic and molecular-target-based screening approaches to identify the co-receptor for JC virus, the causative agent of PML.
Bhatnagar, A. et al. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J. Biol. Chem. 276, 8269–8277 (2001).
Summerbell, C. D., Youle, M., McDonald, V., Catalan, J. & Gazzard, B. G. Megestrol acetate versus cyproheptadine in the treatment of weight loss associated with HIV infection. Int. J. STD AIDS 3, 278–280 (1992).
Couzin, J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306, 384–385 (2004).
Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581–588 (1997).
Devereux, R. B. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339, 765–766 (1998).
Rothman, R. B. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836–2841 (2000).
Setola, V. et al. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223–1229 (2003).
Fitzgerald, L. W. et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75–81 (2000).
Launay, J. M. et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Med. 8, 1129–1135 (2002).
Newman-Tancredi, A. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes. J. Pharmacol. Exp. Ther. 303, 815–822 (2002).
Flowers, C. M., Racoosin, J. A., Lu, S. L. & Beitz, J. G. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin. Proc. 78, 730–731 (2003).
Van Camp, G. et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363, 1179–1183 (2004).
Horvath, J. et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 19, 656–662 (2004).
Clineschmidt, B. V., Hanson, H. M., Pflueger, A. B. & McGuffin, J. C. Anorexigenic and ancillary actions of MK-212 (6-chloro-2-(1-piperazinyl)-pyrazine; CPP). Psychopharmacology (Berl.) 55, 27–33 (1977).
Dourish, C. T. Multiple serotonin receptors: opportunities for new treatments for obesity? Obes. Res. 3, S449–S462 (1995).
Vickers, S. P., Clifton, P. G., Dourish, C. T. & Tecott, L. H. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology (Berl.) 143, 309–314 (1999).
Roth, B. L. & Shapiro, D. A. Insights into the structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development. Exp. Opin. Ther. Targets 5, 685–695 (2001).
Combs, C. K., Bates, P., Karlo, J. C. & Landreth, G. E. Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem. Int. 39, 449–457 (2001).
Yan, Q. et al. Anti-inflammatory drug therapy alters b-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504–7509 (2003).
Kukar, T. et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Ab42 production. Nature Med. 11, 545–550 (2005).
Glaser, V. Immune Control pursues seotonin antagonists. Genet. Eng. News 24 [online], <http://www.immunecontrol.com/icigen.pdf> (2004).
Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y. & Roth, B. L. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl.) 178, 451–460 (2005).
Eash, S. et al. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am. J. Pathol. 164, 419–428 (2004).
Acknowledgements
The authors thank D. Sheffler for figures related to the JC virus life cycle, W. Kroeze for editorial assistance and grants from the National Institutes of Health and the National Institute of Mental Health-Psychoactive Drug Screening Program for supporting the work in the authors' lab.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.L.R. is a co-inventor listed on patents related to serotonin-selective ligands for use in neuropsychiatric and other disorders.
Related links
Related links
DATABASES
Entrez Gene
OMIM
FURTHER INFORMATION
Glossary
- PHENOTYPIC SCREENS
-
A type of chemical screen in which cell responses, such as motility or membrane ruffling, are monitored as an index of drug action. Frequently, phenotypic screens are carried out using high-throughput microscopy and automated image capture and analysis.
- MOLECULAR TARGET-BASED SCREENS
-
A type of chemical screen in which a single molecular target, such as a receptor or enzyme, is screened using a simplified readout such as fluorescence.
- RECEPTOROMICS AND RECEPTOROME
-
Receptorome refers, ultimately, to the entire complement of 'receptors in the genome', although it is more commonly applied to that portion of the genome encoding G-protein-coupled receptors. Receptoromics represents tools and methods of analysis to study the receptorome.
- KINOMICS AND KINOME
-
The kinome refers to the entire complement of protein kinases in a particular genome. Kinomics represents tools and methods of analysis to study the kinome.
- COUNTER-SCREENING
-
The approach of screening candidate medications against an array of molecular targets to identify 'off-target' actions.
Rights and permissions
About this article
Cite this article
O'Connor, K., Roth, B. Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery. Nat Rev Drug Discov 4, 1005–1014 (2005). https://doi.org/10.1038/nrd1900
Issue Date:
DOI: https://doi.org/10.1038/nrd1900
This article is cited by
Clinical connectivity map for drug repurposing: using laboratory results to bridge drugs and diseases
BMC Medical Informatics and Decision Making (2021)
Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements
3 Biotech (2021)
Repurposing existing drugs for COVID-19: an endocrinology perspective
BMC Endocrine Disorders (2020)
Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5
BMC Cancer (2017)
In silico pharmacology: drug design and discovery’s gate to the future
In Silico Pharmacology (2013)